Merck, Moderna claim ‘promising’ skin cancer vaccine results in key trial
Both the FDA and the European Medicines Agency have placed the therapy on an expedited review pathway.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on torontosun.com — the content belongs to Toronto Sun.